iShares MSCI Taiwan ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? iShares MSCI Taiwan ETF trades at $114.58 (market cap $12.87B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: iShares MSCI Taiwan ETF is far larger — about 5.6× SELLAS Life Sciences Group Inc. Common Stock's market cap, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| EWT | SLS | |
|---|---|---|
Market Cap | $12.87B | $2.28B |
Volume | 4,043,927 | 3,128,960 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $15.46 |
52-Week Low | $60.03 | $1.39 |
Typical Hold Time | 52 Days | — |
Enterprise Value | — | $2.15B |
Signals from Pluang's Aura AI — not financial advice
EWT trades at $116.24, down 1.16% today, with a bullish technical outlook supported by moving averages. The ETF remains heavily concentrated in Taiwan's semiconductor sector, particularly TSMC, benefiting from AI-driven demand. Recent news highlights continued US-Taiwan economic cooperation and institutional buying interest.
The outlook remains positive given Taiwan's strategic position in AI supply chains, though geopolitical tensions pose significant risks. Valuation appears reasonable for tech exposure, but investors must weigh semiconductor cyclicality against long-term growth potential in artificial intelligence infrastructure.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →